Skip to main content
no upcoming events

Please check back with us.

PIPELINE > TRIAL OVERVIEW

Trial Information
Molecule Overview
Biomarker Testing
KRAS G12C Inhibitor
Olomorasib
undefined

Peng SB, et al1; Kano Y, et al2; Janes MR, et al3; Ji J, et al4

Target

KRAS is the most common oncogene across all tumor types. KRAS G12C represents a KRAS mutation in patients with non-small cell lung cancer (14%), colorectal cancer (3%), and other solid tumors (1%-3%).4

Molecule

Olomorasib is a selective covalent inhibitor of KRAS G12C; in preclinical models, it shows activity as monotherapy and in combination with other anticancer therapies. It has competitive pharmacokinetic properties supporting its advancement into clinical testing. Olomorasib has been shown in vitro to target a KRAS G12C mutation, thereby inhibiting mutant KRAS-dependent signaling.1

Clinical Development

Olomorasib is being studied in a clinical trial in patients with non-small cell lung cancer, colorectal cancer, or other solid tumors.

References

  1. Peng SB, et al. Cancer Res. 2021;81(suppl 13):1259.
  2. Kano Y, et al. Nat Commun. 2019;10(1):224.
  3. Janes MR, et al. Cell. 2018;172(3):578-589.
  4. Ji J, et al. Onco Targets Ther. 2022;15:747-756.
Clinical Development

Olomorasib is being studied in a clinical trial in patients with non-small cell lung cancer, colorectal cancer, or other solid tumors.

References

  1. Peng SB, et al. Cancer Res. 2021;81(suppl 13):1259.
  2. Kano Y, et al. Nat Commun. 2019;10(1):224.
  3. Janes MR, et al. Cell. 2018;172(3):578-589.
  4. Ji J, et al. Onco Targets Ther. 2022;15:747-756.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial